Quantcast

Industry news that matters to you.  Learn more

MicroRNA Pattern Identified as a Marker for Lung Cancer

Preliminary work has identified a pattern of micro (mi)RNA as a biomarker for lung cancer. A serum-based assay to determine the pattern is minimally invasive and, if fully validated, could offer a way to identify early stages of the disease.

New Test May Help Patients With RA Avoid Useless Treatment

A network of rheumatology practitioners is teaming up with several pharmaceutical companies to evaluate a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from treatment with antitumor necrosis factor-alpha (anti-TNF) agents. This could help clinicians avoid exposing individual patients to adverse effects from drugs unlikely to be effective, reduce healthcare costs, and quickly identify patients who would be candidates for other regimens or for clinical trials of new agents.

Caris Life Sciences Expands Caris Target Now Biomarker Panel to Help Address Therapeutic Dilemmas Facing Nearly One Half of Breast Cancer Patients

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced a significant expansion to the panel of breast cancer biomarkers analyzed by Caris Target Now. The expansion includes 14 new biomarkers that provide physicians with key information to help guide therapeutic decisions for an increased number of breast cancer patients, making the novel theranostic tool now potentially useful to approximately 50 percent of all women battling the disease.

New Clinical Data for Septin9 Colorectal Cancer Blood Test Presented at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company’s proprietary Septin9 biomarker for the blood-based detection of colorectal cancer were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

Neogenix Oncology to Present Data on the Detection of Colorectal and Pancreatic Cancer at ASCO’s 2010 Annual Meeting on Molecular Makers in Cancer

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.